Filing summary: TenX Keane Acquisition, Inc. — Form 10-Q
Important identity discrepancy: The request identifies Citius Oncology, Inc., but the supplied filing is for TenX Keane Acquisition, a Cayman Islands special purpose acquisition company (SPAC). This summary reflects the supplied filing, not Citius Oncology.
Business context and reporting period
The filing covers the quarter ended September 30, 2022. TenX Keane was formed to pursue a business combination and had not begun operating by quarter-end. The IPO closed after the reporting period, on October 18, 2022.
Financial results and position
- Revenue: None; the company had not commenced operations and expected no operating revenue before a business combination.
- Profit and expenses: No expenses or net loss were reported for the three or nine months ended September 30, 2022. For the comparable inception-to-September 2021 period, net loss was $10,113.
- Cash flow and cash: No cash activity or operating cash flow was reported for the first nine months of 2022; cash was $0 at September 30, 2022.
- Assets and liabilities: Total assets were $256,745, all deferred offering costs. Current liabilities were $266,858, including $193,164 due to the Sponsor and $73,694 of accrued formation costs. The balance sheet reports total shareholders’ deficit of $10,113.
- Debt and liquidity: No long-term debt or working-capital loans were outstanding. The company relied on Sponsor advances and anticipated IPO proceeds to fund its activities. The filing reports substantial doubt about the company’s ability to continue as a going concern.
- Margins: Not meaningful because the company had no revenue.
Changes and subsequent events
- Deferred offering costs increased to $256,745 from $126,422 at December 31, 2021.
- On October 18, 2022, the company sold 6.6 million IPO units for gross proceeds of $66.0 million and completed a private placement of 394,000 units for $3.94 million.
- Following the offering, $67.32 million was placed in the trust account. The filing states approximately $700,000 was available outside the trust for expenses and the search for a target.
- IPO transaction costs totaled $4,859,330, including cash underwriting fees, non-cash underwriting shares and other offering costs.
Outlook, risks and other notable items
- Management intended to use trust funds primarily to complete a business combination. The stated deadline was nine months from the IPO closing, extendable to 18 months; if no deal is completed within the applicable period, the company must redeem public shares and wind up, subject to the filing’s terms.
- Management said it expected increased public-company and target-search expenses after the IPO. It cautioned that further financing might be needed, including to complete a larger-than-funded transaction or address substantial shareholder redemptions.
- Management concluded there was substantial doubt about the company’s ability to continue as a going concern because successful completion of a business combination within the permitted period was uncertain.
- The filing notes that COVID-19 could adversely affect the company or its target search, but the impact was not determinable.
- Disclosure controls and procedures were assessed as effective as of September 30, 2022; no material change in internal control was reported. No legal proceedings or defaults upon senior securities were reported.
Investor verification points
- Confirm the issuer: the supplied filing is for TenX Keane Acquisition, not Citius Oncology.
- Check subsequent filings for IPO trust-account balances, use of funds and any business-combination announcement or deadline extension.
- Verify the status and terms of any Sponsor advances, potential working-capital loans, and the disclosed going-concern uncertainty.
- Review the financial statements directly for an apparent inconsistency in the shareholders’ deficit rollforward: its September 30 accumulated-deficit figure does not reconcile clearly with the balance sheet and reported 2022 results.